GLP-1 RETSEPTOR AGONISTLARINING 2-TIP QANDLI DIABET VA SEMIZLIK TERAPIYASIDAGI ZAMONAVIY O‘RNI

Mohira Dadaxo`jayeva

Authors

Mohira Dadaxo`jayeva Akademik Yo.X.Turakulov nomidagi Endokrinologiya markazi Author

Keywords:

GLP-1 retseptor agonistlari, inkretinomimetiklar, semaglutid, tirzepatid, 2-tip qandli diabet

Abstract

Klinik endokrinologiyaning bugungi kundagi eng og‘riqli nuqtalaridan biri - metabolik sindrom, xususan, 2-tip qandli diabet va semizlik epidemiologiyasining shiddat bilan kengayib borayotganidir. Mazkur patologiyalar nafaqat hayot sifatini pasaytiradi, balki kardiorenal asoratlar tufayli nogironlik va erta o‘lim ko’rsatkichlarini keskin oshiradi. Ushbu sharhda glyukagonga o‘xshash peptid-1 (GLP-1) retseptor agonistlarining biologik tabiati, terapevtik samarasi hamda zamonaviy kardiometabolik tibbiyotdagi yetakchi roli tizimli tahlil qilingan. 2020–2025-yillardagi randomizatsiyalangan klinik sinovlar (RCT), jumladan, LEADER, SUSTAIN, SELECT hamda SURPASS dasturlari natijalari umumlashtirilib, semaglutid va tirzepatid kabi molekulalarning nafaqat glikemik nazorat, balki tana vaznini bariatrik ko‘rsatkichlar darajasigacha kamaytirishdagi inqilobiy imkoniyatlari yoritilgan. Shuningdek, preparatlarning xavfsizlik profili, gastrointestinal nojo‘ya ta’sirlari va O‘zbekiston sog‘liqni saqlash tizimida ushbu ilg‘or terapiyani joriy etishning istiqbollari hamda iqtisodiy jihatlari tanqidiy baholangan

Downloads

Download data is not yet available.

References

2025, 48(Suppl. 1), S1–S320.

2. Marso S. P., Daniels G. H., Brown-Frandsen K., et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER Trial). New England Journal of Medicine, 2016, 375(4), 311–322.

3. Dahlof B., Kristensen S. L., et al. Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity who do not have Diabetes (SELECT Trial). The Lancet, 2024, 403(10432), 1125–1136.

4. Wilding J. P. H., Batterham R. L., Calanna S., et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial). New England Journal of Medicine, 2021, 384(11), 989–1001.

5. Frías J. P., Davies M. J., Rosenstock J., et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021, 385(6), 503–515.

6. Gerstein H. C., Colhoun H. M., Dagenais G. R., et al. Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND Trial). The Lancet, 2019, 394(10193), 121–130.

7. Jastreboff A. M., Aronne L. J., Ahmad N. N., et al. Triple GIP, GLP-1, and Glucagon Receptor Agonist Retatrutide for Obesity — Phase 2 Trial Results. New England Journal of Medicine, 2023, 389(6), 514–526.

8. EASD/ADA Consensus Report. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Report by the American Diabetes Association (ADADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2024, 67(1), 3–21.